Jove
Visualize
Contact Us

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.7K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.7K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

1.1K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.1K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

699
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
699
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.0K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.0K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

780
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
780
Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

3.7K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety.

Neuropharmacology·2013
Same author

The unique effect of methiothepin on the terminal serotonin autoreceptor in the rat hypothalamus could be an example of inverse agonism.

Journal of psychopharmacology (Oxford, England)·2012
Same author

Inhibition of TNF-alpha induced-adhesion molecules by Avène Thermal Spring Water in human endothelial cells.

Journal of the European Academy of Dermatology and Venereology : JEADV·2010
Same author

Effects of scopolamine treatment and lesion of the nucleus basalis upon various cholinergic markers in the rat brain cortex.

Neurochemistry international·2010
Same author

TLR2 sensing of F. nucleatum and S. sanguinis distinctly triggered gingival innate response.

Cytokine·2009
Same author

Problems associated with long-term treatment with selective serotonin reuptake inhibitors.

Journal of psychopharmacology (Oxford, England)·2008
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 28, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.8K

In vivo [(3)H]ketanserin binding: effect of modifying synaptic serotonin levels.

M B Assie1, M Charveron, M Briley

  • 1Department of Biochemical Pharmacology, Centre de Recherche Pierre Fabre, 17 Avenue Jean Moulin 81100 Castres, France.

Neurochemistry International
|May 27, 2010
PubMed
Summary

[(3)H]ketanserin binding in vivo is inhibited by direct serotonin agonists but not by indirect ones. This suggests [(3)H]ketanserin may not accurately reflect synaptic serotonin levels when using indirect-acting antidepressants.

More Related Videos

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
12:21

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram

Published on: November 27, 2016

15.6K
Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

9.3K

Related Experiment Videos

Last Updated: Feb 28, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.8K
Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
12:21

Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram

Published on: November 27, 2016

15.6K
Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

9.3K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Antidepressant therapies often target increasing monoamine levels in the brain.
  • Measuring synaptic monoamine concentrations directly is challenging.
  • [(3)H]ketanserin, a 5HT(2) serotonin receptor antagonist, is used indirectly to estimate synaptic serotonin.

Purpose of the Study:

  • To investigate whether in vivo binding of [(3)H]ketanserin is inhibited by increased synaptic serotonin levels.
  • To determine if [(3)H]ketanserin binding accurately reflects synaptic serotonin changes induced by various serotonergic agents.

Main Methods:

  • Tested the effect of direct and indirect serotonin-elevating compounds on [(3)H]ketanserin binding in mice.
  • Administered various agents including quipazine, methysergide, mianserin, monoamine oxidase inhibitors, serotonin uptake blockers, serotonin releasers, and 5-hydroxytryptophan.
  • Measured [(3)H]ketanserin binding in vitro and in vivo, alongside observing serotonin-induced behaviors.

Main Results:

  • Directly acting serotonin agents (quipazine, methysergide, mianserin) inhibited [(3)H]ketanserin binding in vitro and in vivo.
  • Indirectly acting agents (MAO inhibitors, SSRIs, releasers, precursor) did not affect [(3)H]ketanserin binding in vivo, despite causing behavioral changes.
  • Significant serotonin-induced behaviors were observed with indirect agents, indicating their efficacy in raising synaptic serotonin.

Conclusions:

  • In vivo [(3)H]ketanserin binding is insensitive to synaptic serotonin level changes induced by indirect-acting serotonergic drugs.
  • The serotonin receptor sites labeled by [(3)H]ketanserin in vivo may not be associated with the nerve terminals targeted by these indirect agonists.
  • [(3)H]ketanserin's utility as an indirect measure of synaptic serotonin may be limited, particularly with certain classes of antidepressants.